CGEM240719C35000
- 2.14
- 0.000.00%
Cullinan Therapeutics Newsroom
Cullinan Therapeutics(CGEM.US) Officer Sells US$130.64K in Common Stock
$Cullinan Therapeutics(CGEM.US)$ Officer Michaelson Jennifer sold 8,000 shares of common stock on Jul 5, 2024 at an average price of $16.33 for a total value of $130.64K.Source: Announcement What is
Institutional Owners May Ignore Cullinan Therapeutics, Inc.'s (NASDAQ:CGEM) Recent US$92m Market Cap Decline as Longer-term Profits Stay in the Green
Stifel Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $40
Stifel analyst Bradley Canino maintains $Cullinan Therapeutics(CGEM.US)$ with a buy rating, and maintains the target price at $40.According to TipRanks data, the analyst has a success rate of 44.2% an
TD Cowen Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating
TD Cowen analyst Marc Frahm maintains $Cullinan Therapeutics(CGEM.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 47.0% and a total average return of 23.7% over th
HC Wainwright & Co.: Reiterated its buy rating on Cullinan Therapeutics (CGEM.US), adjusting the target price from $28.00 to $28.00.
HC Wainwright & Co.: Reiterated its buy rating on Cullinan Therapeutics (CGEM.US), adjusting the target price from $28.00 to $28.00.
Reported Saturday, Cullinan Therapeutics Announced Initial Data From Pivotal Phase 2b REZILIENT1 Study Of Zipalertinib
As of a January 12, 2024 data cut-off, 31 patients had been enrolled. Patients had received a median of three prior systemic anti-cancer regimens, including prior platinum-based chemotherapy, prior an
Cullinan Therapeutics publishes positive preliminary data from Zipalertinib's critical phase 2B Rezilient1 study
Cullinan Therapeutics publishes positive preliminary data from Zipalertinib's critical phase 2B Rezilient1 study
Express News | Cullinan Therapeutics Announces Positive Initial Data From Pivotal Phase 2B Rezilient1 Study of Zipalertinib
Cullinan Therapeutics Announces Positive Initial Data From Pivotal Phase 2b REZILIENT1 Study of Zipalertinib
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced positive initial data in patients receiving zipalertinib after prior treatment with amivantamab enrolled in its pivotal Phase 2b REZILIENT1 clinical trial.
Viking, CRISPR, Intellia Among Potential M&A Targets: Wells Fargo
Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit
CAMBRIDGE, Mass., May 24, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that Nadim Ahmed,
HC Wainwright & Co. Reiterates Buy on Cullinan Therapeutics, Maintains $28 Price Target
HC Wainwright & Co. analyst Edward White reiterates Cullinan Therapeutics with a Buy and maintains $28 price target.
H.C. Wainwright Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $28
H.C. Wainwright analyst Edward White maintains $Cullinan Therapeutics(CGEM.US)$ with a buy rating, and maintains the target price at $28.According to TipRanks data, the analyst has a success rate of 3
Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination With a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024
Preliminary data from CLN-619 in combination with checkpoint inhibitor pembrolizumab show objective responses in patients with tumor types that are typically unresponsive to pembrolizumab, such as non-small cell lung
Cullinan Therapeutics Files to Sell 14.4M Shares of Common Stock for Holders
Cullinan Therapeutics Shares Are Trading Lower After the Company Reported Q1 Results and Provided a Corporate Update.
Cullinan Therapeutics Shares Are Trading Lower After the Company Reported Q1 Results and Provided a Corporate Update.
Cullinan Oncology Is Maintained at Buy by HC Wainwright & Co.
Cullinan Oncology Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on Cullinan Therapeutics, Lowers Price Target to $28
HC Wainwright & Co. analyst Edward White maintains Cullinan Therapeutics with a Buy and lowers the price target from $29 to $28.
Wedbush Reiterates Outperform on Cullinan Therapeutics, Maintains $36 Price Target
Wedbush analyst Robert Driscoll reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Outperform and maintains $36 price target.
Cullinan Therapeutics | 10-Q: Quarterly report